<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591330</url>
  </required_header>
  <id_info>
    <org_study_id>12857</org_study_id>
    <secondary_id>H8Y-MC-HBCY</secondary_id>
    <nct_id>NCT01591330</nct_id>
  </id_info>
  <brief_title>A Study of LY2140023 in Healthy Males and Females</brief_title>
  <official_title>A Particle Size Study of 3 Different Particle Size Test Tablet Formulations Compared to the Reference Tablet Formulation in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denovo Biopharma LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denovo Biopharma LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate the effect of different particle size of LY2140023. The study&#xD;
      involves 4 single doses of 80 milligrams (mg) LY2140023 taken as 1 tablet by mouth with a&#xD;
      washout period of at least 3 days between doses. This study will last approximately 60 days&#xD;
      not including screening. Screening is required within 30 days prior to study entry.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY2140023</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Last Time Point of Measurable Concentration (AUC[0-tlast]) of LY2140023</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum Concentration (Cmax) of LY404039 (Active Moiety)</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Last Time Point of Measurable Concentration (AUC[0-tlast]) of LY404039 (Active Moiety)</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2140023</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Terminal Half Life (t1/2) of LY2140023</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Apparent Total Body Clearance (CL/F) of LY2140023</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Volume of Distribution During the Terminal Phase (Vz/F) of LY2140023</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of Maximum Observed Drug Concentrations (Tmax) of LY404039 (Active Moiety)</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Terminal Half Life (t1/2) of LY404039 (Active Moiety)</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Apparent Total Body Clearance (CL/F) of LY404039 (Active Moiety)</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Volume of Distribution During the Terminal Phase (Vz/F) of LY404039 (Active Moiety)</measure>
    <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>LY2140023 Reference Form</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2140023: 80 mg, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2140023 Test-Low</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2140023: 80 mg, low particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2140023 Test-Medium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2140023: 80 mg, medium particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY2140023 Test-High</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY2140023: 80 mg, high particle size, administered once, orally. There is a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023 Reference form</intervention_name>
    <description>80-mg tablet administered orally</description>
    <arm_group_label>LY2140023 Reference Form</arm_group_label>
    <other_name>LY2140023 Monohydrate (Reference)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023 Test-Low</intervention_name>
    <description>80-mg tablet administered orally</description>
    <arm_group_label>LY2140023 Test-Low</arm_group_label>
    <other_name>LY2140023 Monohydrate (Test - Low)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023 Test-Medium</intervention_name>
    <description>80-mg tablet administered orally</description>
    <arm_group_label>LY2140023 Test-Medium</arm_group_label>
    <other_name>LY2140023 Monohydrate (Test - Medium)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY2140023 Test-High</intervention_name>
    <description>80-mg tablet administered orally</description>
    <arm_group_label>LY2140023 Test-High</arm_group_label>
    <other_name>LY2140023 Monohydrate (Test - High)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  are overtly healthy males or females, as determined by medical history and physical&#xD;
             examination&#xD;
&#xD;
          -  male participants: agree to use a reliable method of birth control during the study&#xD;
             and for 3 months following the last dose of LY2140023 and agree not to donate sperm&#xD;
             for 3 months following the last dose of LY2140023&#xD;
&#xD;
          -  female participants:&#xD;
&#xD;
               -  female participants of child-bearing potential who test negative for pregnancy at&#xD;
                  screening and agree to use a reliable method of birth control for the duration of&#xD;
                  the study and for at least 3 months after the last dose of LY2140023&#xD;
&#xD;
               -  female participants who are of non-childbearing potential (that is,&#xD;
                  postmenopausal or permanently sterile following hysterectomy, bilateral&#xD;
                  salpingectomy, or confirmed tubal occlusion [not tubal ligation]). Postmenopausal&#xD;
                  is defined as no menses for at least 1 year, or a plasma follicle stimulating&#xD;
                  hormone (FSH) value of &gt;40 milli-international units per liter (mIU/mL), unless&#xD;
                  the participant is taking hormone replacement therapy&#xD;
&#xD;
          -  have a body mass index (BMI) of 19 to 32 kilograms per meter squared (kg/m^2),&#xD;
             inclusive, at the time of screening&#xD;
&#xD;
          -  have clinical laboratory test results within normal reference ranges for the&#xD;
             population or investigator site or results with acceptable deviations that are judged&#xD;
             to be not clinically significant by the investigator&#xD;
&#xD;
          -  have venous access sufficient to allow for blood sampling as per the protocol&#xD;
&#xD;
          -  are reliable and willing to make themselves available for the duration of the study&#xD;
             and are willing to follow study procedures&#xD;
&#xD;
          -  have given written informed consent approved by Lilly and the chosen ethical review&#xD;
             board (ERB)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  are currently enrolled in or have completed or discontinued within the last 90 days&#xD;
             from a clinical trial involving an investigational product, or are concurrently&#xD;
             enrolled in any other type of medical research judged not to be scientifically or&#xD;
             medically compatible with this study&#xD;
&#xD;
          -  have known allergies to LY2140023, LY404039, related compounds, or any components of&#xD;
             the formulation&#xD;
&#xD;
          -  are persons who have previously completed or withdrawn from this study or any other&#xD;
             study investigating LY2140023 and have previously received the investigational product&#xD;
&#xD;
          -  have an abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the&#xD;
             investigator, increases the risks associated with participating in the study&#xD;
&#xD;
          -  have an abnormal blood pressure or pulse rate as determined by the investigator&#xD;
&#xD;
          -  have a history or presence of cardiovascular, respiratory, hepatic, renal,&#xD;
             gastrointestinal, endocrine, hematological, or neurological disorders capable of&#xD;
             significantly altering the absorption, metabolism, or elimination of drugs; of&#xD;
             constituting a risk when taking the study medication; or of interfering with the&#xD;
             interpretation of data&#xD;
&#xD;
          -  have evidence or any history of significant active neuropsychiatric disease&#xD;
&#xD;
          -  have increased risk of seizures based on a history of:&#xD;
&#xD;
               -  one or more seizures (except for a single simple febrile seizure [lacking&#xD;
                  focality and lasting less than 15 minutes, not associated with a central nervous&#xD;
                  system (CNS) infection or severe metabolic disturbance] as a child between ages 6&#xD;
                  months to 5 years)&#xD;
&#xD;
               -  head trauma with loss of consciousness or a post-concussive syndrome within 1&#xD;
                  year or lifetime history of head trauma with persistent neurological deficit&#xD;
                  (focal or diffuse)&#xD;
&#xD;
               -  uncontrolled migraine or transient ischemic attack (TIA) within 1 year and/or&#xD;
                  stroke with persistent neurological deficit (focal or diffuse); uncontrolled&#xD;
                  migraine is defined as migraine attacks that produce headache lasting up to 72&#xD;
                  hours and are often accompanied by associated symptoms (nausea, photophobia, and&#xD;
                  phonophobia) that impair well-being and disrupt social functioning; TIA is&#xD;
                  defined as &quot;mini-stroke&quot; caused by temporary disturbance of blood supply to an&#xD;
                  area of the brain, which results in a sudden, brief decrease in brain function&#xD;
&#xD;
               -  CNS infection with persistent neurological deficit (focal or diffuse)&#xD;
&#xD;
               -  brain surgery&#xD;
&#xD;
               -  electroencephalogram (EEG) with paroxysmal (epileptiform) activity (isolated&#xD;
                  spikes waves, repetitive bursts of sharp waves, paroxysmal activity, frank&#xD;
                  seizures, spike-wave complexes, or sharp-slow wave complexes, or as locally&#xD;
                  defined)&#xD;
&#xD;
               -  brain structural lesion, including developmental abnormalities, as determined by&#xD;
                  examination or imaging studies (except hydrocephalus treated by shunt or without&#xD;
                  neurological deficits).&#xD;
&#xD;
          -  show evidence or any history of known substance dependence or abuse at any time&#xD;
             (according to Diagnostic and Statistical Manual of Mental Disorders [DSM-IV]&#xD;
             diagnosis) or regularly use known drugs of abuse and/or show positive findings on&#xD;
             urinary drug screening&#xD;
&#xD;
          -  show evidence of human immunodeficiency (HIV) virus infection and/or positive human&#xD;
             HIV antibodies&#xD;
&#xD;
          -  show evidence of hepatitis C and/or positive hepatitis C antibody&#xD;
&#xD;
          -  show evidence of hepatitis B and/or positive hepatitis B surface antigen&#xD;
&#xD;
          -  are women with a positive pregnancy test or women who are lactating&#xD;
&#xD;
          -  intend to use over-the-counter (OTC) or prescription medication within 14 days prior&#xD;
             to dosing of LY2140023&#xD;
&#xD;
          -  have donated blood of more than 500 milliliters (mL) within the 3 months prior to&#xD;
             screening, or plan to donate blood within the 3 months after the last dose&#xD;
&#xD;
          -  have an average weekly alcohol intake that exceeds 28 units per week (males) and 21&#xD;
             units per week (females), or are unwilling to stop alcohol consumption for 48 hours&#xD;
             prior to check-in for each treatment period until discharge in each period (1 unit =&#xD;
             12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled&#xD;
             spirits)&#xD;
&#xD;
          -  have a clinically significant abnormality in the neurological examination&#xD;
&#xD;
          -  participants judged prior to randomization to be at suicidal risk by the investigator&#xD;
&#xD;
          -  participants who are unwilling to refrain from tobacco- or nicotine-containing&#xD;
             products while in the Clinical Research Unit (CRU) or are unable to abide by CRU&#xD;
             restrictions&#xD;
&#xD;
          -  show evidence of pruritus or skin exfoliation&#xD;
&#xD;
          -  have an eosinophil count &gt; 1.5 x 10^9 per liter (L)&#xD;
&#xD;
          -  show evidence of active renal disease or creatinine clearance (CrCl) less than 90&#xD;
             milliliters per minute (mL/min) (as calculated by the Cockcroft-Gault equation)&#xD;
&#xD;
          -  in the opinion of the investigator or sponsor, are unsuitable for inclusion in the&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Leeds</city>
        <state>West Yorkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>May 2, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <results_first_submitted>August 25, 2021</results_first_submitted>
  <results_first_submitted_qc>August 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">September 21, 2021</results_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sequence 1</title>
          <description>LY2140023 80 milligrams (mg) reference form (RF) in Period 1, LY2140023 80 mg Test-low in Period 2, LY2140023 80 mg Test-medium in Period 3, LY2140023 80 mg Test-high in Period 4.&#xD;
Each LY2140023 dose was administered once, orally. There was a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.</description>
        </group>
        <group group_id="P2">
          <title>Sequence 2</title>
          <description>LY2140023 80 mg Test-low in Period 1, LY2140023 80 mg Test-high in Period 2, LY2140023 80 mg RF Period 3, LY2140023 80 mg Test-medium in Period 4.&#xD;
Each LY2140023 dose was administered once, orally. There was a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.</description>
        </group>
        <group group_id="P3">
          <title>Sequence 3</title>
          <description>LY2140023 80 mg Test-high in Period 1, LY2140023 80 mg Test-medium in Period 2, LY2140023 80 mg Test-low in Period 3, LY2140023 80 mg RF in Period 4.&#xD;
Each LY2140023 dose was administered once, orally. There was a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.</description>
        </group>
        <group group_id="P4">
          <title>Sequence 4</title>
          <description>LY2140023 80 mg Test-medium in Period 1, LY2140023 80 mg RF in Period 2, LY2140023 80 mg Test-high in Period 3, LY2140023 80 mg Test-low in Period 4.&#xD;
Each LY2140023 dose was administered once, orally. There was a minimum 3-day washout period between dosing in one period and dosing in the next dosing period.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least 1 Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout of at Least 3 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout of at Least 3 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout of at Least 3 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 4</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All participants who received at least 1 dose of study drug</population>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>All participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms (kg)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71.71" spread="13.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI is an estimate of body fat based on body weight divided by height squared.</description>
          <units>kilograms per meter squared (kg/m^2)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.73" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY2140023</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY2140023</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
          <units>nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277" spread="25"/>
                    <measurement group_id="O2" value="290" spread="23"/>
                    <measurement group_id="O3" value="304" spread="37"/>
                    <measurement group_id="O4" value="284" spread="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Last Time Point of Measurable Concentration (AUC[0-tlast]) of LY2140023</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Last Time Point of Measurable Concentration (AUC[0-tlast]) of LY2140023</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
          <units>nanograms*hours per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1200" spread="28"/>
                    <measurement group_id="O2" value="1190" spread="30"/>
                    <measurement group_id="O3" value="1210" spread="32"/>
                    <measurement group_id="O4" value="1210" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY404039 (Active Moiety)</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Maximum Concentration (Cmax) of LY404039 (Active Moiety)</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="476" spread="14"/>
                    <measurement group_id="O2" value="485" spread="17"/>
                    <measurement group_id="O3" value="494" spread="17"/>
                    <measurement group_id="O4" value="490" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Last Time Point of Measurable Concentration (AUC[0-tlast]) of LY404039 (Active Moiety)</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Area Under the Concentration Versus Time Curve From Zero to Last Time Point of Measurable Concentration (AUC[0-tlast]) of LY404039 (Active Moiety)</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2640" spread="17"/>
                    <measurement group_id="O2" value="2640" spread="19"/>
                    <measurement group_id="O3" value="2710" spread="17"/>
                    <measurement group_id="O4" value="2700" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2140023</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of LY2140023</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
          <units>hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="5.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.00" upper_limit="5.02"/>
                    <measurement group_id="O3" value="3.00" lower_limit="1.00" upper_limit="7.00"/>
                    <measurement group_id="O4" value="3.00" lower_limit="2.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Terminal Half Life (t1/2) of LY2140023</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Terminal Half Life (t1/2) of LY2140023</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.13" lower_limit="1.61" upper_limit="3.27"/>
                    <measurement group_id="O2" value="1.93" lower_limit="1.55" upper_limit="2.95"/>
                    <measurement group_id="O3" value="2.02" lower_limit="1.47" upper_limit="3.06"/>
                    <measurement group_id="O4" value="2.13" lower_limit="1.43" upper_limit="3.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Apparent Total Body Clearance (CL/F) of LY2140023</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Apparent Total Body Clearance (CL/F) of LY2140023</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
          <units>liters per hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.8" spread="28"/>
                    <measurement group_id="O2" value="67.0" spread="30"/>
                    <measurement group_id="O3" value="65.9" spread="32"/>
                    <measurement group_id="O4" value="66.2" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Volume of Distribution During the Terminal Phase (Vz/F) of LY2140023</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Volume of Distribution During the Terminal Phase (Vz/F) of LY2140023</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY2140023 plasma concentration data.</population>
          <units>Liters (L)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="205" spread="25"/>
                    <measurement group_id="O2" value="187" spread="23"/>
                    <measurement group_id="O3" value="192" spread="26"/>
                    <measurement group_id="O4" value="204" spread="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Time of Maximum Observed Drug Concentrations (Tmax) of LY404039 (Active Moiety)</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Time of Maximum Observed Drug Concentrations (Tmax) of LY404039 (Active Moiety)</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="3.00" upper_limit="5.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Terminal Half Life (t1/2) of LY404039 (Active Moiety)</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Terminal Half Life (t1/2) of LY404039 (Active Moiety)</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.10" lower_limit="2.46" upper_limit="4.24"/>
                    <measurement group_id="O2" value="3.05" lower_limit="2.35" upper_limit="4.79"/>
                    <measurement group_id="O3" value="2.95" lower_limit="2.39" upper_limit="4.11"/>
                    <measurement group_id="O4" value="3.07" lower_limit="2.71" upper_limit="3.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Apparent Total Body Clearance (CL/F) of LY404039 (Active Moiety)</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Apparent Total Body Clearance (CL/F) of LY404039 (Active Moiety)</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="17"/>
                    <measurement group_id="O2" value="19.3" spread="19"/>
                    <measurement group_id="O3" value="18.9" spread="17"/>
                    <measurement group_id="O4" value="18.9" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics: Volume of Distribution During the Terminal Phase (Vz/F) of LY404039 (Active Moiety)</title>
        <time_frame>Predose and at 0.5, 1, 2, 3, 4, 5, 6, 7, 9, 12, 16, and 24 hours postdose</time_frame>
        <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
        <group_list>
          <group group_id="O1">
            <title>LY2140023 Reference Form</title>
            <description>LY2140023: 80 milligrams (mg), administered once, orally.</description>
          </group>
          <group group_id="O2">
            <title>LY2140023 Test-Low</title>
            <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
          </group>
          <group group_id="O3">
            <title>LY2140023 Test-Medium</title>
            <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
          </group>
          <group group_id="O4">
            <title>LY2140023 Test-High</title>
            <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics: Volume of Distribution During the Terminal Phase (Vz/F) of LY404039 (Active Moiety)</title>
          <population>All participants who received at least 1 dose of study drug, did not vomit within 5 hours postdose, and have evaluable LY404039 (active moiety) plasma concentration data following administration of LY2140023.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="28"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.3" spread="28"/>
                    <measurement group_id="O2" value="85.0" spread="32"/>
                    <measurement group_id="O3" value="80.4" spread="26"/>
                    <measurement group_id="O4" value="83.6" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>LY2140023 Reference Form</title>
          <description>LY2140023: 80 mg, administered once, orally.</description>
        </group>
        <group group_id="E2">
          <title>LY2140023 Test-Low</title>
          <description>LY2140023: 80 mg, low particle size, administered once, orally.</description>
        </group>
        <group group_id="E3">
          <title>LY2140023 Test-Medium</title>
          <description>LY2140023: 80 mg, medium particle size, administered once, orally.</description>
        </group>
        <group group_id="E4">
          <title>LY2140023 Test-High</title>
          <description>LY2140023: 80 mg, high particle size, administered once, orally.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="32"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="35"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="33"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="32"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" events="9" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" events="10" subjects_affected="6" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="35"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="35"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="33"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E4" events="8" subjects_affected="5" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

